Shares of Nabriva Therapeutics PLC – (NASDAQ:NBRV) have been assigned an average rating of “Buy” from the eleven research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $9.00.
A number of brokerages recently commented on NBRV. BidaskClub raised Nabriva Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research downgraded Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Nabriva Therapeutics in a report on Thursday, May 9th. Northland Securities set a $13.00 target price on Nabriva Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 8th. Finally, ValuEngine downgraded Nabriva Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.
Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $29,000. HRT Financial LLC acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $31,000. Two Sigma Advisers LP acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $37,000. Parametric Portfolio Associates LLC increased its position in Nabriva Therapeutics by 82.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 18,616 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 8,396 shares during the period. Finally, Paloma Partners Management Co acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $54,000. Institutional investors and hedge funds own 4.61% of the company’s stock.
NBRV traded up $0.13 on Monday, reaching $2.78. The company’s stock had a trading volume of 182,004 shares, compared to its average volume of 1,117,286. The company has a market capitalization of $1.92 billion, a P/E ratio of -1.71 and a beta of 2.42. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $6.05. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.11 and a current ratio of 5.55.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $0.56 million. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. As a group, equities research analysts forecast that Nabriva Therapeutics will post -1.18 earnings per share for the current fiscal year.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
See Also: Dividend Aristocrat Index